Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates

Transfusion

Volumn 48, Issue 6, 2008, Pages 1220-1226

  Berting, Andreas ^a   Modrof, Jens ^a   Unger, Ulrike ^a   Gessner, Matthias ^a   Klotz, Andreas ^a   Poelsler, Gerhard ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; VIRUS RNA;

ARTICLE; CELL LINE; GENOTYPE; HEAT TREATMENT; INOCULATION; NANOFILTER; NONHUMAN; PARVOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VAPOR; VIRUS DETECTION; VIRUS INACTIVATION;

BLOOD DONORS; ENZYME INHIBITORS; FACTOR VIII; FILTRATION; FREEZE DRYING; GENOTYPE; HEAT; KINETICS; NANOSTRUCTURES; PARVOVIRUS B19, HUMAN; VIRUS INACTIVATION; VOLATILIZATION;

EID: 44849084775     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01662.x     Document Type: Article

References (33)

1. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003 9 : 24 37.
2. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994 67 : 132 8.
3. Kreil TR, Wieser A, Berting A, Spruth M, Medek C, Pölsler G, Gaida T, Hämmerle T, Teschner W, Schwarz HP, Barrett PN. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion 2006 46 : 1143 51.
4. Omar A, Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002 42 : 1005 10.
5. Yokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N, Tomono T. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004 86 : 225 9.
6. Weimer T, Streichert S, Watson C, Groner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001 41 : 1500 4.
7. Aubin JT, Defer C, Vidaud M, Maniez MM, Flan B. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang 2000 78 : 7 12.
8. Wong S, Brown KE. Development of an improved method of detection of infectious parvovirus B19. J Clin Virol 2006 35 : 407 13.
9. CPMP. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95/Rev. London : The European Agency for the Evaluation of Medicinal Products 1996.
10. Roberts PL, Hart H. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 2000 28 : 185 8.
11. Blumel J, Schmidt I, Willkommen H, Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002 42 : 1011 8.
12. Yunoki M, Tsujikawa M, Urayama T, Sasaki Y, Morita M, Tanaka H, Hattori S, Takechi K, Ikuta K. Heat sensitivity of human parvovirus B19. Vox Sang 2003 84 : 164 9.
13. Prikhod'ko GG, Vasilyeva I, Reyes H, Wong S, Brown KE, Jameson T, Busby TF. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion 2005 45 : 1011 9.
14. Nguyen QT, Sifer C, Schneider V, Allaume X, Servant A, Bernaudin F, Auguste V, Garbarg-Chenon A. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999 37 : 2483 7.
15. Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002 301 : 374 80.
16. Servant A, Laperche S, Lallemand F, Marinho V, De Saint MG, Meritet JF, Garbarg-Chenon A. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002 76 : 9124 34.
17. Blumel J, Eis-Hubinger AM, Stuhler A, Bonsch C, Gessner M, Lower J. Characterization of parvovirus B19 genotype 2 in KU812Ep6 cells. J Virol 2005 79 : 14197 206.
18. Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S, Aberham C, Gessner M, Kreil TR. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion 2008 48 : 178 86.
19. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986 58 : 921 36.
20. Ozawa K, Ayub J, Hao YS, Kurtzman G, Shimada T, Young N. Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol 1987 61 : 2395 406.
21. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975 1 : 72 3.
22. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004 350 : 586 97.
23. Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol 2000 12 : 289 94.
24. Pankuweit S, Ruppert V, Eckhardt H, Strache D, Maisch B. Pathophysiology and aetiological diagnosis of inflammatory myocardial diseases with a special focus on parvovirus B19. J Vet Med Infect Dis Vet Public Health 2005 52 : 344 7.
25. PPTA voluntary standard parvovirus B19. Report No. 017677. Annapolis (MD) : Plasma Protein Therapeutics Association 2001 Feb 8.
26. Groner A, Gurtler L. Parvovirus B19 infection and virus safety of plasma preparations. Biomed Prog 2000 13 : 46 50.
27. Blumel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, Lower J, Eis-Hubinger AM. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002 42 : 1473 81.
28. Boschetti N, Niederhauser I, Kempf C, Stuhler A, Lower J, Blumel J. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 2004 44 : 1079 86.
29. Hattori S, Yunoki M, Tsujikawa M, Urayama T, Tachibana Y, Yamamoto I, Yamamoto S, Ikuta K. Variability of parvovirus B19 to inactivation by liquid heating in plasma products. Vox Sang 2007 92 : 121 4.
30. Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA. Novel parvovirus and related variant in human plasma. Emerg Infect Dis 2006 12 : 151 4.
31. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005 102 : 12891 6.
32. Schneider B, Becker M, Brackmann HH, Eis-Hubinger AM. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb Haemost 2004 92 : 838 45.
33. Ekman A, Hokynar K, Kakkola L, Kantola K, Hedman L, Bondén H, Gessner M, Aberham C, Norja P, Miettinen S, Hedman K, Söderlund-Venermo M. Biological and immunological relation of human parvovirus B19 genotypes 1-3. J Virol 2007 81 : 6927 35.